Orforglipron Hemicalcium Hydrate Powder

Orforglipron hemicalcium hydrate is the crystalline calcium salt hydrate form of orforglipron free base. It is the optimized pharmaceutical active pharmaceutical ingredient (API) solid form, developed to improve chemical stability, crystallinity, solubility and powder flowability compared with the free-base compound. This hemicalcium hydrate crystalline powder is the preferred solid form for drug formulation and pharmaceutical research.

GLP-1 Receptor Agonist Activity It is a potent, orally active non-peptide glucagon-like peptide 1 receptor agonist. It selectively activates GLP-1 receptors to stimulate glucose-dependent insulin secretion and suppress excessive glucagon release, lowering blood glucose levels without significant hypoglycemia risk.

Appetite Suppression and Weight Reduction By acting on hypothalamic feeding centers, it delays gastric emptying, curbs food craving and reduces total calorie intake, leading to sustained body weight and fat mass loss.

Improvement of Metabolic Syndrome It enhances peripheral insulin sensitivity, reduces visceral fat accumulation, and lowers blood lipid levels to ameliorate overall metabolic dysfunction.

Cardiometabolic Protection It alleviates chronic low-grade inflammation and oxidative stress, helping reduce cardiovascular risks associated with obesity and type 2 diabetes.

Pharmaceutical R&D API Material This crystalline hemicalcium hydrate powder is the standard bulk raw material used in preclinical studies, formulation development, stability testing and Phase I–III clinical trials. Its stable crystal structure avoids polymorph transformation during tablet compression.

Solid Dosage Form Development This salt hydrate exhibits superior thermal and chemical stability, low hygroscopicity, and consistent dissolution rate. It is used to manufacture oral tablets for type 2 diabetes and chronic obesity treatment.

Laboratory Pharmacology Research It is used in in vitro receptor binding assays, cell experiments and animal model pharmacodynamic and pharmacokinetic tests.

Pharmaceutical Quality Research It serves as the reference crystalline form for polymorph screening, impurity analysis and long-term stability studies of orforglipron drug substances.

General Administration Rules

Administration route: Oral dosing once daily, taken with or without food.

Gradual dose titration is required to minimize gastrointestinal adverse reactions. Each dose level should be maintained for at least 4 weeks before dose escalation.

Reduce the dosage if persistent nausea, vomiting and diarrhea occur.

1. Clinical Dosage for Obesity Treatment

Initial starting dose: 1 mg (free base equivalent) once daily

Step 1 titration: 3 mg once daily

Step 2 titration: 6 mg once daily

Standard maintenance dose: 12 mg once daily

High therapeutic dose: 24 mg once daily

Maximum trial dose: 36 mg once daily

The 12 mg to 24 mg daily dose is the most commonly used regimen for steady weight loss with acceptable tolerability.

2. Clinical Dosage for Type 2 Diabetes Mellitus

The same slow titration schedule applies.

Low maintenance dose for glycemic control: 3 mg daily

Standard therapeutic dose: 12 mg daily

Maximum dose for combined blood sugar control and weight loss: 36 mg daily

3. Dosage Adjustment for Special Populations

Patients with mild or moderate hepatic and renal impairment: No mandatory dose reduction; begin with the lowest starting dose and slow down titration progress.

Elderly patients aged 65 years and older: Initiate treatment at 1 mg daily and avoid rapid dose increases.

Patients with gastrointestinal disorders: Stay at low to medium maintenance doses to reduce digestive side effects.

4. Preclinical Animal Dosage (API Powder Testing)

For oral rodent experiments: 1 mg/kg to 15 mg/kg body weight per day, calculated as free base equivalent.

5. Key Reminder for Hemicalcium Hydrate Salt

Since hemicalcium hydrate contains calcium and crystal water, the weighed mass of the salt powder must be converted to match the free-base target concentration when preparing formulations. Do not use the raw salt powder directly for oral administration.

Orforglipron hemicalcium hydrate is the crystalline API salt form used to manufacture oral tablets. The dosage below refers to the equivalent mass of the parent orforglipron free base in clinical trials. Pure hemicalcium hydrate powder cannot be taken directly by humans without pharmaceutical formulation. All dosing regimens are based on Phase 2 and Phase 3 clinical trial protocols.

Higher chemical stability than orforglipron free base under high temperature and humidity storage conditions.

Better crystallinity with less amorphous content, which guarantees consistent bioavailability.

Improved physical processing properties for tableting and capsule filling in pharmaceutical production.

Important Precondition

Orforglipron hemicalcium hydrate is the crystalline calcium hydrate salt form of orforglipron API. Its pharmacological profile and adverse reactions are identical to the free-base molecule. All side effect data are sourced from Phase 2 and Phase 3 clinical trials. This bulk powder is only for pharmaceutical formulation research, and direct oral intake is forbidden.

1. Most Common Adverse Reactions (Gastrointestinal, Dose-Related)

These symptoms mainly arise during dose escalation and tend to ease after the patient adapts to the drug:

Nausea: The most prevalent adverse reaction, occurring frequently in medium and high-dose groups.

Constipation, vomiting, diarrhea, abdominal distension, dyspepsia, acid reflux and flatulence.

Reduced appetite leading to mild food intake decline.

Slow dose titration can greatly lower the incidence of gastrointestinal discomfort. Approximately 5% to 8% of trial participants discontinued treatment due to persistent digestive issues.

2. Common Mild Systemic Side Effects

Headache and persistent fatigue.

Mild tachycardia: a slight rise in resting heart rate, usually without obvious discomfort.

Transient dehydration caused by vomiting and diarrhea, which may lead to temporary fluctuations in renal function.

Occasional mild hypotension, especially when combined with antihypertensive drugs.

Temporary hair thinning in long-term medication users.

Low risk of hypoglycemia when used alone; hypoglycemia risk rises when combined with insulin or sulfonylurea antidiabetic drugs.

3. Rare but Severe Adverse Events (Class risks of GLP-1 receptor agonists)

Acute pancreatitis. Patients suffering from continuous severe upper abdominal pain must stop medication immediately and receive medical examination.

Gallstone disease and acute cholecystitis, which are associated with rapid body weight loss during treatment.

Acute kidney injury secondary to severe gastrointestinal fluid loss.

Potential risk of medullary thyroid carcinoma. This product should not be used by people with a personal or family history of thyroid tumors.

Rare hypersensitivity reactions including rash and pruritus.

4. Dose Correlation of Side Effects

Low daily dose (1–6 mg): Only mild nausea and constipation; low treatment withdrawal rate.

Medium daily dose (12 mg): Balanced efficacy and tolerability, the preferred maintenance dose in clinical trials.

High daily dose (24–36 mg): Markedly increased incidence of vomiting and gastrointestinal irritation.

5. Special Population Precautions

Patients with chronic gastritis, irritable bowel syndrome and peptic ulcers have poorer gastrointestinal tolerance and should stay on low doses.

Pregnant and lactating women should avoid this product entirely.

Patients with hepatic or renal impairment need slower dose escalation and regular physical monitoring.

Concomitant use with other GLP-1 agonists is prohibited, as overlapping toxicity will aggravate adverse reactions.

Orforglipron hemicalcium hydrate is a crystalline calcium salt hydrate form of orforglipron. The calcium and water components only optimize physical and chemical stability and do not exert any pharmacological effects. After oral administration, the salt dissociates rapidly in digestive fluid to release free orforglipron, the active small-molecule ingredient.

1. Core Target

Orforglipron is an orally active non-peptide agonist targeting the glucagon-like peptide-1 receptor (GLP‑1R). It binds selectively to GLP‑1 receptors distributed in the pancreas, brain, gastrointestinal tract, skeletal muscle and adipose tissue, and activates the cAMP intracellular signaling pathway.

2. Glycemic-lowering Mechanism

It stimulates pancreatic beta cells to secrete insulin only when blood glucose rises. This glucose-dependent insulin secretion minimizes the risk of hypoglycemia.

It inhibits glucagon secretion from pancreatic alpha cells, cutting down excess glucose production by the liver.

These combined actions effectively reduce fasting and postprandial blood glucose levels for type 2 diabetes therapy.

3. Weight-loss Mechanism

It acts on GLP‑1 receptors in the hypothalamus to suppress hunger signals and reduce food craving.

It slows gastric emptying, prolonging satiety and lowering total calorie intake.

Continuous reduction of food intake leads to gradual fat loss and body weight reduction.

4. Improvement of Insulin Resistance

It improves the sensitivity of liver and muscle tissue to insulin. It reduces visceral fat deposition and lowers blood lipid levels, which helps reverse metabolic abnormalities caused by obesity.

5. Cardiometabolic Benefit

Activation of GLP‑1 receptors alleviates vascular oxidative stress and chronic low-grade inflammation. It improves multiple cardiovascular risk factors in patients with diabetes and obesity.

Merits of Hemicalcium Hydrate Crystal Form

Low hygroscopicity and high chemical stability during long-term bulk storage.

Stable dissolution rate to guarantee consistent oral bioavailability after being made into oral tablets.

Excellent flow property suitable for large-scale pharmaceutical manufacturing.

Other Nootropics Raw Material Also Available

Delivery Time:Around 3-5 workdays after your payment.

Package:1kg/aluminium foil bag;25Kgs in fiber-drums with two-plastic bags inside

Net Weight:25kgs/Drum/Gross Weight:28kgs/Drum

Drum Size & Volume:I.D.42cm × H52cm,0.08 m³/Drum

Storage:Stored in dry and cool place,keep away from strong light and heat.

Shelf Life:Two years when properly stored.

Hot Tags: orforglipron hemicalcium hydrate powder, China orforglipron hemicalcium hydrate powder manufacturers, suppliers, factory, 4 Aminobenzoic Acid for Skincare, Povidone Iodine for Medical Use, Pramoxine HCl for Skin Itching Relief, Tetrahydrocurcumin for Anti aging, Tetrahydrocurcumin for Anti wrinkle Effects, Tetrahydrocurcumin for Anti-aging